SHANGHAI, China, April. 14, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, today announced that the preliminary clinical data on its investigational PD-1 inhibitor Geptanolimab would be presented at the 111st American Association for Cancer Research (AACR) Annual meeting. Among which the data on PTCL will be orally presented by Dr. Shi Yuankai at online annual meeting on April. 28 at the clinical trials plenary sessions.
The two clinical trials to be presented are designed to evaluate the efficacy and safety of Geptanolimab monotherapy in relapsed/refractory peripheral T cell Lymphoma (PTCL) and in relapsed/refractory alveola soft part sarcoma (ASPS), separately. The preliminary clinical data and detailed trial design will be presented in posters at the AACR annual meeting in April, 2020. PTCL clinical data will be presented orally on April. 28 (EDT).
- The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial: GB226 in patients with PTCL.
- The efficacy and safety of Geptanolimab (GB226) in patients with recurrent/metastatic/unresectable alveolar soft partsarcoma (ASPS): A multicenter, open-label, single-arm, phase 2 trial: GB226 in patients with ASPS.
“Genor is the first biopharmaceutical company in China to apply PD-1 for PTCL, while relapsed/refractory patients represent significant unmet medical needs globally. So far, neither US FDA nor Chinese NMPA has approved any PD-1 in this setting.” Said Dr. Joe Xinhua Zhou, founder and president of Genor. “I am glad that clinical data would be announced for the first time at the AACR in 2020. We remain committed in addressing unmet medical need in China and globally, with our differentiated clinical development strategies for Geptanolimab.”
About Genor Biopharma
Genor Biopharma Co. Ltd (“Genor”) is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. Genor has successfully developed drug candidates targeting pathways with blockbuster potentials, encompassing top three oncology targets and five out of the ten bestselling drugs globally. Genor has leveraged primarily in-house capabilities in establishing a pipeline of 15 targeted drug candidates with tremendous commercialization potentials in China that cover both proven and novel biological pathways.
This press release contains forward-looking statements which reflect Genor Biopharma's current expectations regarding future events, including its expectations for the clinical development of Geptanolimab. Forward-looking statements involve risks and uncertainties. Genor Biopharma undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.